back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2017-05-18 Tx date 2017-05-08 |
$SL
Supreme Pharmaceuticals Inc. |
Factor, Ronald A.
4 - Director of Issuer
Holder: RSP account (Indirect Ownership)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
9,000 | ||
| Filed 2017-05-18 Tx date 2017-05-08 |
$SL
Supreme Pharmaceuticals Inc. |
Factor, Ronald A.
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
125,000 | ||
| Filed 2017-05-18 Tx date 2017-05-08 |
$SL
Supreme Pharmaceuticals Inc. |
Factor, Ronald A.
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2017-05-18 Tx date 2017-05-08 |
$SL
Supreme Pharmaceuticals Inc. |
Factor, Ronald A.
4 - Director of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
125,000 | ||
| Filed 2017-05-18 Tx date 2017-05-08 |
$SL
Supreme Pharmaceuticals Inc. |
Factor, Ronald A.
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2016-12-22 Tx date 2016-12-16 |
$SL
Supreme Pharmaceuticals Inc. |
Rifici, Charles
4 - Director of Issuer
Holder: Chuck Rifici Holdings Inc. (Indirect Ownership)
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
+2,316,160 vol |
4,316,160 | |
| Filed 2016-12-22 Tx date 2016-12-16 |
$SL
Supreme Pharmaceuticals Inc. |
Rifici, Charles
4 - Director of Issuer
Holder: Chuck Rifici Holdings Inc. (Indirect Ownership)
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
+2,316,160 vol |
||
| Filed 2016-12-22 Tx date 2016-12-16 |
$SL
Supreme Pharmaceuticals Inc. |
Rifici, Charles
4 - Director of Issuer
Holder: Chuck Rifici Holdings Inc. (Indirect Ownership)
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
2,000,000 | ||
| Filed 2016-12-22 Tx date 2016-12-16 |
$SL
Supreme Pharmaceuticals Inc. |
Rifici, Charles
4 - Director of Issuer
Holder: Chuck Rifici Holdings Inc. (Indirect Ownership)
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
+2,316,160 vol |
||
| Filed 2016-12-22 Tx date 2016-12-16 |
$SL
Supreme Pharmaceuticals Inc. |
Rifici, Charles
4 - Director of Issuer
Holder: Chuck Rifici Holdings Inc. (Indirect Ownership)
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2016-12-22 Tx date 2016-12-16 |
$SL
Supreme Pharmaceuticals Inc. |
Rifici, Charles
4 - Director of Issuer
Holder: Chuck Rifici Holdings Inc. (Indirect Ownership)
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2016-12-22 Tx date 2016-12-16 |
$SL
Supreme Pharmaceuticals Inc. |
Rifici, Charles
4 - Director of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
28,125 | ||
| Filed 2016-12-21 Tx date 2016-12-16 |
$SL
Supreme Pharmaceuticals Inc. |
Rifici, Charles
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2016-12-21 Tx date 2016-12-16 |
$SL
Supreme Pharmaceuticals Inc. |
Rifici, Charles
4 - Director of Issuer
Holder: Chuck Rifici Holdings Inc. (Indirect Ownership)
|
Convertible Debentures
00 - Opening Balance-Initial SEDI Report
|
$3,008,000 | ||
| Filed 2016-12-21 Tx date 2016-12-16 |
$SL
Supreme Pharmaceuticals Inc. |
Rifici, Charles
4 - Director of Issuer
Holder: Chuck Rifici Holdings Inc. (Indirect Ownership)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
2,000,000 | ||
| Filed 2016-12-21 Tx date 2016-12-16 |
$SL
Supreme Pharmaceuticals Inc. |
Rifici, Charles
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2016-12-21 Tx date 2016-12-16 |
$SL
Supreme Pharmaceuticals Inc. |
Rifici, Charles
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2016-12-21 Tx date 2016-12-16 |
$SL
Supreme Pharmaceuticals Inc. |
Rifici, Charles
4 - Director of Issuer
Direct Ownership
|
Convertible Debentures
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2016-12-21 Tx date 2016-12-16 |
$SL
Supreme Pharmaceuticals Inc. |
Rifici, Charles
4 - Director of Issuer
Direct Ownership
|
Convertible Debentures
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2016-12-21 Tx date 2016-12-16 |
$SL
Supreme Pharmaceuticals Inc. |
Rifici, Charles
4 - Director of Issuer
Direct Ownership
|
Convertible Debentures
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2016-12-21 Tx date 2016-12-16 |
$SL
Supreme Pharmaceuticals Inc. |
Rifici, Charles
4 - Director of Issuer
Direct Ownership
|
Convertible Debentures
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2016-12-21 Tx date 2016-12-16 |
$SL
Supreme Pharmaceuticals Inc. |
Rifici, Charles
4 - Director of Issuer
Holder: Chuck Rifici Holdings Inc. (Indirect Ownership)
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
+2,316,160 vol |
4,344,285 | |
| Filed 2016-12-21 Tx date 2016-12-16 |
$SL
Supreme Pharmaceuticals Inc. |
Rifici, Charles
4 - Director of Issuer
Holder: Chuck Rifici Holdings Inc. (Indirect Ownership)
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
2,028,125 | ||
| Filed 2016-12-21 Tx date 2016-12-16 |
$SL
Supreme Pharmaceuticals Inc. |
Rifici, Charles
4 - Director of Issuer
Holder: Chuck Rifici Holdings Inc. (Indirect Ownership)
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
+2,316,160 vol |
||
| Filed 2016-12-21 Tx date 2016-12-16 |
$SL
Supreme Pharmaceuticals Inc. |
Rifici, Charles
4 - Director of Issuer
Holder: Chuck Rifici Holdings Inc. (Indirect Ownership)
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
+2,316,160 vol |
||
| Filed 2016-12-21 Tx date 2016-12-16 |
$SL
Supreme Pharmaceuticals Inc. |
Rifici, Charles
4 - Director of Issuer
Holder: Chuck Rifici Holdings Inc. (Indirect Ownership)
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2016-12-21 Tx date 2016-12-16 |
$SL
Supreme Pharmaceuticals Inc. |
Rifici, Charles
4 - Director of Issuer
Holder: Chuck Rifici Holdings Inc. (Indirect Ownership)
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2016-12-21 Tx date 2016-12-16 |
$SL
Supreme Pharmaceuticals Inc. |
Rifici, Charles
4 - Director of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
+2,316,160 vol |
||
| Filed 2016-12-21 Tx date 2016-12-16 |
$SL
Supreme Pharmaceuticals Inc. |
Rifici, Charles
4 - Director of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
+2,316,160 vol |
||
| Filed 2016-12-21 Tx date 2016-12-16 |
$SL
Supreme Pharmaceuticals Inc. |
Rifici, Charles
4 - Director of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2016-12-21 Tx date 2016-12-16 |
$SL
Supreme Pharmaceuticals Inc. |
Rifici, Charles
4 - Director of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2016-12-21 Tx date 2016-12-16 |
$SL
Supreme Pharmaceuticals Inc. |
Rifici, Charles
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+300,000 vol |
300,000 | |
| Filed 2016-12-19 Tx date 2016-12-16 |
$SL
Supreme Pharmaceuticals Inc. |
Fowler, John Alexander
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+2,300,000 vol |
3,750,000 | |
| Filed 2016-12-19 Tx date 2016-12-16 |
$SL
Supreme Pharmaceuticals Inc. |
Walters, Scott Robertson
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+800,000 vol |
1,237,500 | |
| Filed 2016-12-19 Tx date 2016-12-16 |
$SL
Supreme Pharmaceuticals Inc. |
La Brier, Michael John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+1,000,000 vol |
2,291,250 | |
| Filed 2016-12-19 Tx date 2016-12-16 |
$SL
Supreme Pharmaceuticals Inc. |
Dhaliwal, Navdeep S.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+2,000,000 vol |
3,040,858 | |
| Filed 2016-12-16 Tx date 2016-04-25 |
$SL
Supreme Pharmaceuticals Inc. |
La Brier, Michael John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Hunter's Glen Investments Inc. (Indirect Ownership)
|
Convertible Debentures
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2016-12-16 Tx date 2016-12-13 |
$SL
Supreme Pharmaceuticals Inc. |
Weidelich, Cynthia
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
+15,400 vol |
15,400 | |
| Filed 2016-12-16 Tx date 2016-10-29 |
$SL
Supreme Pharmaceuticals Inc. |
Weidelich, Cynthia
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2016-12-16 Tx date 2016-12-13 |
$SL
Supreme Pharmaceuticals Inc. |
Weidelich, Cynthia
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Convertible Debentures
16 - Acquisition or disposition under a prospectus exemption
|
$
+$20,000 vol $1,000 each |
$20,000 | |
| Filed 2016-12-16 Tx date 2016-10-29 |
$SL
Supreme Pharmaceuticals Inc. |
Weidelich, Cynthia
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Convertible Debentures
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2016-12-16 Tx date 2016-12-13 |
$SL
Supreme Pharmaceuticals Inc. |
La Brier, Michael John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Hunter's Glen Investments Inc. (Indirect Ownership)
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
+770,000 vol |
5,770,000 | |
| Filed 2016-12-16 Tx date 2016-12-13 |
$SL
Supreme Pharmaceuticals Inc. |
La Brier, Michael John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Hunter's Glen Investments Inc. (Indirect Ownership)
|
Convertible Debentures
16 - Acquisition or disposition under a prospectus exemption
|
$
+$1,000,000 vol $1,000 each |
$1,000,000 | |
| Filed 2016-12-16 Tx date 2016-12-13 |
$SL
Supreme Pharmaceuticals Inc. |
Fowler, John Alexander
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: 8986207 Canada Inc. (Indirect Ownership)
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
+38,500 vol |
38,500 | |
| Filed 2016-12-16 Tx date 2014-06-02 |
$SL
Supreme Pharmaceuticals Inc. |
Fowler, John Alexander
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: 8986207 Canada Inc. (Indirect Ownership)
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2016-12-16 Tx date 2016-12-13 |
$SL
Supreme Pharmaceuticals Inc. |
Fowler, John Alexander
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: 8986207 Canada Inc. (Indirect Ownership)
|
Convertible Debentures
16 - Acquisition or disposition under a prospectus exemption
|
$
+$50,000 vol $1,000 each |
$50,000 | |
| Filed 2016-12-16 Tx date 2014-06-02 |
$SL
Supreme Pharmaceuticals Inc. |
Fowler, John Alexander
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: 8986207 Canada Inc. (Indirect Ownership)
|
Convertible Debentures
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2016-12-16 Tx date 2016-12-13 |
$SL
Supreme Pharmaceuticals Inc. |
Dhaliwal, Navdeep S.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
+26,950 vol |
76,950 | |
| Filed 2016-12-16 Tx date 2016-12-13 |
$SL
Supreme Pharmaceuticals Inc. |
Dhaliwal, Navdeep S.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Convertible Debentures
16 - Acquisition or disposition under a prospectus exemption
|
$
+$35,000 vol $1,000 each |
$35,000 | |
| Filed 2016-12-16 Tx date 2015-11-16 |
$SL
Supreme Pharmaceuticals Inc. |
Dhaliwal, Navdeep S.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Convertible Debentures
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2016-10-17 Tx date 2016-10-14 |
$SL
Supreme Pharmaceuticals Inc. |
Herburger, Peter
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-58,279.68
-40,472 vol $1.44 each |
2,259,557 | |
| Filed 2016-10-14 Tx date 2016-10-07 |
$SL
Supreme Pharmaceuticals Inc. |
Herburger, Peter
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$122,999
+300,000 vol $0.41 each |
2,300,029 | |
| Filed 2016-10-14 Tx date 2016-10-11 |
$SL
Supreme Pharmaceuticals Inc. |
Herburger, Sarah
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-30,800
-20,000 vol $1.54 each |
2,125,425 | |
| Filed 2016-10-14 Tx date 2016-10-07 |
$SL
Supreme Pharmaceuticals Inc. |
Herburger, Peter
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Options
51 - Exercise of options
|
-300,000 vol |
355,000 | |
| Filed 2016-10-07 Tx date 2016-10-05 |
$SL
Supreme Pharmaceuticals Inc. |
Herburger, Sarah
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-27,000
-20,000 vol $1.35 each |
2,185,425 | |
| Filed 2016-10-07 Tx date 2016-10-05 |
$SL
Supreme Pharmaceuticals Inc. |
Herburger, Sarah
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-28,400
-20,000 vol $1.42 each |
2,145,425 | |
| Filed 2016-10-07 Tx date 2016-10-05 |
$SL
Supreme Pharmaceuticals Inc. |
Herburger, Sarah
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-28,200
-20,000 vol $1.41 each |
2,165,425 | |
| Filed 2016-10-07 Tx date 2016-10-05 |
$SL
Supreme Pharmaceuticals Inc. |
Herburger, Peter
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-121,878
-99,900 vol $1.22 each |
2,000,029 | |
| Filed 2016-10-04 Tx date 2016-10-03 |
$SL
Supreme Pharmaceuticals Inc. |
Herburger, Peter
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-26,500
-25,000 vol $1.06 each |
2,099,929 | |
| Filed 2016-10-04 Tx date 2016-10-03 |
$SL
Supreme Pharmaceuticals Inc. |
Herburger, Peter
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-52,500
-50,000 vol $1.05 each |
2,124,929 | |
| Filed 2016-09-16 Tx date 2016-09-14 |
$SL
Supreme Pharmaceuticals Inc. |
Dhaliwal, Navdeep S.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
54 - Exercise of warrants
|
$10,000
+20,000 vol $0.50 each |
177,800 | |
| Filed 2016-09-16 Tx date 2016-09-09 |
$SL
Supreme Pharmaceuticals Inc. |
La Brier, Michael John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Wendy La Brier (Control or Direction)
|
Convertible Debentures mature April 23, 2018
36 - Conversion or exchange
|
-$250,000 vol |
$0 | |
| Filed 2016-09-16 Tx date 2016-09-09 |
$SL
Supreme Pharmaceuticals Inc. |
La Brier, Michael John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Wendy La Brier (Control or Direction)
|
Common Shares
36 - Conversion or exchange
|
$249,999
+1,470,588 vol $0.17 each |
5,425,706 | |
| Filed 2016-09-16 Tx date 2016-09-14 |
$SL
Supreme Pharmaceuticals Inc. |
Dhaliwal, Navdeep S.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Warrants exercisable at $0.50 per share prior to September 22, 2016
54 - Exercise of warrants
|
-20,000 vol |
0 | |
| Filed 2016-09-16 Tx date 2016-09-14 |
$SL
Supreme Pharmaceuticals Inc. |
Dhaliwal, Navdeep S.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Warrants exercisable at $0.50 per share prior to November 5, 2016
54 - Exercise of warrants
|
-19,200 vol |
0 | |
| Filed 2016-09-16 Tx date 2016-09-14 |
$SL
Supreme Pharmaceuticals Inc. |
Dhaliwal, Navdeep S.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
54 - Exercise of warrants
|
$9,600
+19,200 vol $0.50 each |
197,000 | |
| Filed 2016-09-16 Tx date 2016-09-14 |
$SL
Supreme Pharmaceuticals Inc. |
Dhaliwal, Navdeep S.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
40 - Short sale
|
$-32,144
-39,200 vol $0.82 each |
157,800 | |
| Filed 2016-09-15 Tx date 2016-09-14 |
$SL
Supreme Pharmaceuticals Inc. |
Herburger, Peter
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-48,600
-60,000 vol $0.81 each |
2,214,929 | |
| Filed 2016-09-15 Tx date 2016-09-14 |
$SL
Supreme Pharmaceuticals Inc. |
Herburger, Peter
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-16,600
-20,000 vol $0.83 each |
2,174,929 | |
| Filed 2016-09-15 Tx date 2016-09-14 |
$SL
Supreme Pharmaceuticals Inc. |
Herburger, Peter
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-16,400
-20,000 vol $0.82 each |
2,194,929 | |
| Filed 2016-09-15 Tx date 2016-09-14 |
$SL
Supreme Pharmaceuticals Inc. |
Herburger, Peter
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-16,000
-20,000 vol $0.80 each |
2,274,929 | |
| Filed 2016-09-02 Tx date 2016-08-29 |
$SL
Supreme Pharmaceuticals Inc. |
Dhaliwal, Navdeep S.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$20,000
+50,000 vol $0.40 each |
||
| Filed 2016-09-02 Tx date 2016-08-29 |
$SL
Supreme Pharmaceuticals Inc. |
Walters, Scott Robertson
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+137,500 vol |
437,500 | |
| Filed 2016-09-02 Tx date 2016-08-30 |
$SL
Supreme Pharmaceuticals Inc. |
La Brier, Michael John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Hunter's Glen Investments Inc. (Indirect Ownership)
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
+2,500,000 vol |
5,000,000 | |
| Filed 2016-09-02 Tx date 2016-08-29 |
$SL
Supreme Pharmaceuticals Inc. |
La Brier, Michael John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+791,250 vol |
1,291,250 | |
| Filed 2016-09-02 Tx date 2016-08-30 |
$SL
Supreme Pharmaceuticals Inc. |
La Brier, Michael John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Hunter's Glen Investments Inc. (Indirect Ownership)
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$1,000,000
+2,500,000 vol $0.40 each |
5,600,000 | |
| Filed 2016-09-02 Tx date 2016-08-29 |
$SL
Supreme Pharmaceuticals Inc. |
Herburger, Sarah
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Options
50 - Grant of options
|
+100,000 vol |
350,000 | |
| Filed 2016-09-02 Tx date 2016-08-29 |
$SL
Supreme Pharmaceuticals Inc. |
Herburger, Peter
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Options
50 - Grant of options
|
+205,000 vol |
655,000 | |
| Filed 2016-09-02 Tx date 2016-08-29 |
$SL
Supreme Pharmaceuticals Inc. |
Gehlsen, Cailin B.
5 - Senior Officer of Issuer
Direct Ownership
|
Options
52 - Expiration of options
|
+100,000 vol |
175,000 | |
| Filed 2016-09-02 Tx date 2016-08-29 |
$SL
Supreme Pharmaceuticals Inc. |
Fowler, John Alexander
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+1,000,000 vol |
1,450,000 | |
| Filed 2016-09-02 Tx date 2016-08-30 |
$SL
Supreme Pharmaceuticals Inc. |
Dhaliwal, Navdeep S.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$20,000
+50,000 vol $0.40 each |
197,000 | |
| Filed 2016-09-02 Tx date 2016-08-29 |
$SL
Supreme Pharmaceuticals Inc. |
Dhaliwal, Navdeep S.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$20,000
+50,000 vol $0.40 each |
||
| Filed 2016-09-02 Tx date 2016-08-30 |
$SL
Supreme Pharmaceuticals Inc. |
Dhaliwal, Navdeep S.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
+50,000 vol |
50,000 | |
| Filed 2016-09-02 Tx date 2015-11-16 |
$SL
Supreme Pharmaceuticals Inc. |
Dhaliwal, Navdeep S.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2016-09-02 Tx date 2016-08-29 |
$SL
Supreme Pharmaceuticals Inc. |
Dhaliwal, Navdeep S.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+740,858 vol |
1,040,858 | |
| Filed 2016-07-29 Tx date 2016-07-26 |
$SL
Supreme Pharmaceuticals Inc. |
Herburger, Sarah
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,125
-2,500 vol $0.45 each |
2,207,925 | |
| Filed 2016-07-29 Tx date 2016-07-27 |
$SL
Supreme Pharmaceuticals Inc. |
Herburger, Sarah
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,125
-2,500 vol $0.45 each |
2,205,425 | |
| Filed 2016-06-23 Tx date 2016-06-20 |
$SL
Supreme Pharmaceuticals Inc. |
Fowler, John Alexander
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
53 - Grant of warrants
|
+50,000 vol |
50,000 | |
| Filed 2016-06-23 Tx date 2016-06-20 |
$SL
Supreme Pharmaceuticals Inc. |
Fowler, John Alexander
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$20,000
+50,000 vol $0.40 each |
2,337,620 | |
| Filed 2016-06-23 Tx date 2014-06-02 |
$SL
Supreme Pharmaceuticals Inc. |
Fowler, John Alexander
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2016-06-23 Tx date 2016-06-20 |
$SL
Supreme Pharmaceuticals Inc. |
La Brier, Michael John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Hunter's Glen Investments Inc. (Indirect Ownership)
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$1,000,000
+2,500,000 vol $0.40 each |
3,100,000 | |
| Filed 2016-06-23 Tx date 2016-04-25 |
$SL
Supreme Pharmaceuticals Inc. |
La Brier, Michael John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Hunter's Glen Investments Inc. (Indirect Ownership)
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2016-06-23 Tx date 2016-06-20 |
$SL
Supreme Pharmaceuticals Inc. |
La Brier, Michael John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Hunter's Glen Investments Inc. (Indirect Ownership)
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
+2,500,000 vol |
2,500,000 | |
| Filed 2016-05-04 Tx date 2016-04-25 |
$SL
Supreme Pharmaceuticals Inc. |
La Brier, Michael John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Wendy La Brier (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
3,955,118 | ||
| Filed 2016-05-04 Tx date 2016-04-25 |
$SL
Supreme Pharmaceuticals Inc. |
La Brier, Michael John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Wendy La Brier (Control or Direction)
|
Warrants exercisable at $0.17 per share prior to April 23, 2020
00 - Opening Balance-Initial SEDI Report
|
2,124,618 | ||
| Filed 2016-05-04 Tx date 2016-04-25 |
$SL
Supreme Pharmaceuticals Inc. |
La Brier, Michael John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Wendy La Brier (Control or Direction)
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
588,235 | ||
| Filed 2016-05-04 Tx date 2016-04-25 |
$SL
Supreme Pharmaceuticals Inc. |
La Brier, Michael John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
500,000 | ||
| Filed 2016-05-04 Tx date 2016-04-25 |
$SL
Supreme Pharmaceuticals Inc. |
La Brier, Michael John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Wendy La Brier (Control or Direction)
|
Convertible Debentures mature April 23, 2018
00 - Opening Balance-Initial SEDI Report
|
$250,000 | ||
| Filed 2016-05-04 Tx date 2016-04-25 |
$SL
Supreme Pharmaceuticals Inc. |
La Brier, Michael John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Hunter's Glen Investments Inc. (Indirect Ownership)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
600,000 | ||
| Filed 2016-04-26 Tx date 2016-04-25 |
$SL
Supreme Pharmaceuticals Inc. |
Herburger, Peter
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$39,000
+100,000 vol $0.39 each |
2,294,929 | |
| Filed 2016-04-26 Tx date 2016-04-25 |
$SL
Supreme Pharmaceuticals Inc. |
Walters, Scott Robertson
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
300,000 | ||
| Filed 2016-04-26 Tx date 2016-04-25 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$58,500
+150,000 vol $0.39 each |
3,693,804 | |
| Filed 2016-03-18 Tx date 2016-03-18 |
$SL
Supreme Pharmaceuticals Inc. |
Dhaliwal, Navdeep S.
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
+100,000 vol |
147,000 | |
| Filed 2016-03-18 Tx date 2016-03-18 |
$SL
Supreme Pharmaceuticals Inc. |
Herburger, Sarah
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
+50,000 vol |
2,210,425 | |
| Filed 2016-03-18 Tx date 2016-03-18 |
$SL
Supreme Pharmaceuticals Inc. |
Herburger, Peter
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
+100,000 vol |
2,194,929 | |
| Filed 2016-03-18 Tx date 2016-03-14 |
$SL
Supreme Pharmaceuticals Inc. |
Herburger, Peter
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-26,400
-60,000 vol $0.44 each |
2,094,929 | |
| Filed 2016-03-18 Tx date 2016-03-18 |
$SL
Supreme Pharmaceuticals Inc. |
Gehlsen, Cailin B.
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
+25,000 vol |
40,000 | |
| Filed 2016-03-18 Tx date 2016-03-18 |
$SL
Supreme Pharmaceuticals Inc. |
Fowler, John Alexander
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
+250,000 vol |
2,287,620 | |
| Filed 2016-03-18 Tx date 2016-03-18 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
+100,000 vol |
3,543,804 | |
| Filed 2016-03-04 Tx date 2015-10-22 |
$SL
Supreme Pharmaceuticals Inc. |
Gehlsen, Cailin B.
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2016-03-04 Tx date 2016-01-10 |
$SL
Supreme Pharmaceuticals Inc. |
Herburger, Sarah
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Options
50 - Grant of options
|
+100,000 vol |
250,000 | |
| Filed 2016-03-04 Tx date 2016-01-10 |
$SL
Supreme Pharmaceuticals Inc. |
Herburger, Peter
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Options
50 - Grant of options
|
+150,000 vol |
450,000 | |
| Filed 2016-03-04 Tx date 2016-01-10 |
$SL
Supreme Pharmaceuticals Inc. |
Gehlsen, Cailin B.
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+75,000 vol |
75,000 | |
| Filed 2016-03-04 Tx date 2016-01-10 |
$SL
Supreme Pharmaceuticals Inc. |
Fowler, John Alexander
8 - Deemed Insider - 6 Months before becoming Insider
Direct Ownership
|
Options
50 - Grant of options
|
+200,000 vol |
450,000 | |
| Filed 2016-03-04 Tx date 2016-01-10 |
$SL
Supreme Pharmaceuticals Inc. |
Dhaliwal, Navdeep S.
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+300,000 vol |
300,000 | |
| Filed 2016-03-04 Tx date 2016-01-10 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+200,000 vol |
500,000 | |
| Filed 2016-03-04 Tx date 2015-11-16 |
$SL
Supreme Pharmaceuticals Inc. |
Dhaliwal, Navdeep S.
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2016-02-10 Tx date 2016-02-10 |
$SL
Supreme Pharmaceuticals Inc. |
Dhaliwal, Navdeep S.
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$2,520
+7,000 vol $0.36 each |
47,000 | |
| Filed 2016-02-10 Tx date 2016-02-10 |
$SL
Supreme Pharmaceuticals Inc. |
Fowler, John Alexander
8 - Deemed Insider - 6 Months before becoming Insider
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$9,000
+25,000 vol $0.36 each |
2,037,620 | |
| Filed 2016-02-10 Tx date 2016-02-10 |
$SL
Supreme Pharmaceuticals Inc. |
Fowler, John Alexander
8 - Deemed Insider - 6 Months before becoming Insider
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$9,250
+25,000 vol $0.37 each |
2,012,620 | |
| Filed 2016-01-29 Tx date 2016-01-29 |
$SL
Supreme Pharmaceuticals Inc. |
Fowler, John Alexander
8 - Deemed Insider - 6 Months before becoming Insider
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-27,600
-60,000 vol $0.46 each |
1,987,620 | |
| Filed 2016-01-29 Tx date 2016-01-29 |
$SL
Supreme Pharmaceuticals Inc. |
Fowler, John Alexander
8 - Deemed Insider - 6 Months before becoming Insider
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-9,300
-20,000 vol $0.465 each |
2,047,620 | |
| Filed 2016-01-29 Tx date 2016-01-29 |
$SL
Supreme Pharmaceuticals Inc. |
Fowler, John Alexander
8 - Deemed Insider - 6 Months before becoming Insider
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-9,400
-20,000 vol $0.47 each |
2,067,620 | |
| Filed 2016-01-15 Tx date 2016-01-12 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-67,200
-140,000 vol $0.48 each |
3,443,804 | |
| Filed 2016-01-13 Tx date 2016-01-08 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-11,160
-24,000 vol $0.465 each |
3,643,804 | |
| Filed 2016-01-13 Tx date 2016-01-11 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-19,200
-40,000 vol $0.48 each |
3,583,804 | |
| Filed 2016-01-13 Tx date 2016-01-11 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-9,500
-20,000 vol $0.475 each |
3,623,804 | |
| Filed 2016-01-13 Tx date 2016-01-08 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-4,700
-10,000 vol $0.47 each |
3,667,804 | |
| Filed 2016-01-08 Tx date 2016-01-05 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-8,490.72
-17,328 vol $0.49 each |
3,683,204 | |
| Filed 2016-01-08 Tx date 2015-12-22 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Warrants exercisable at $0.17 per share prior to April 23, 2020
54 - Exercise of warrants
|
$-221,045.22
-1,300,266 vol $0.17 each |
0 | |
| Filed 2016-01-08 Tx date 2015-12-22 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Common Shares
54 - Exercise of warrants
|
$221,045
+1,300,266 vol $0.17 each |
3,700,532 | |
| Filed 2016-01-08 Tx date 2015-12-22 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Warrants
53 - Grant of warrants
|
+1,300,266 vol |
1,450,266 | |
| Filed 2016-01-08 Tx date 2016-01-07 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-2,592
-5,400 vol $0.48 each |
3,677,804 | |
| Filed 2015-12-01 Tx date 2015-11-27 |
$SL
Supreme Pharmaceuticals Inc. |
Ruimy, James Aaron
8 - Deemed Insider - 6 Months before becoming Insider
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,537.50
-7,500 vol $0.205 each |
1,623,903 | |
| Filed 2015-11-25 Tx date 2015-01-23 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$99,000
+300,000 vol $0.33 each |
2,000,000 | |
| Filed 2015-11-25 Tx date 2015-01-23 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
+150,000 vol |
150,000 | |
| Filed 2015-11-25 Tx date 2014-11-10 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2015-11-24 Tx date 2015-11-16 |
$SL
Supreme Pharmaceuticals Inc. |
Dhaliwal, Navdeep S.
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
40,000 | ||
| Filed 2015-11-24 Tx date 2015-11-16 |
$SL
Supreme Pharmaceuticals Inc. |
Dhaliwal, Navdeep S.
4 - Director of Issuer
Direct Ownership
|
Warrants exercisable at $0.50 per share prior to September 22, 2016
00 - Opening Balance-Initial SEDI Report
|
20,000 | ||
| Filed 2015-11-24 Tx date 2015-11-16 |
$SL
Supreme Pharmaceuticals Inc. |
Dhaliwal, Navdeep S.
4 - Director of Issuer
Direct Ownership
|
Warrants exercisable at $0.50 per share prior to November 5, 2016
00 - Opening Balance-Initial SEDI Report
|
19,200 | ||
| Filed 2015-10-30 Tx date 2015-10-22 |
$SL
Supreme Pharmaceuticals Inc. |
Gehlsen, Cailin B.
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
15,000 | ||
| Filed 2015-10-26 Tx date 2015-10-26 |
$SL
Supreme Pharmaceuticals Inc. |
Ruimy, James Aaron
8 - Deemed Insider - 6 Months before becoming Insider
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,050
-5,000 vol $0.21 each |
1,631,403 | |
| Filed 2015-10-21 Tx date 2015-10-19 |
$SL
Supreme Pharmaceuticals Inc. |
Ruimy, James Aaron
8 - Deemed Insider - 6 Months before becoming Insider
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,050
-5,000 vol $0.21 each |
1,636,403 | |
| Filed 2015-09-23 Tx date 2015-09-18 |
$SL
Supreme Pharmaceuticals Inc. |
Ruimy, James Aaron
8 - Deemed Insider - 6 Months before becoming Insider
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,700
-10,000 vol $0.17 each |
1,641,403 | |
| Filed 2015-08-07 Tx date 2014-11-10 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Warrants exercisable at $0.50 per share prior to September 22, 2015
00 - Opening Balance-Initial SEDI Report
|
650,000 | ||
| Filed 2015-08-07 Tx date 2015-07-30 |
$SL
Supreme Pharmaceuticals Inc. |
Herburger, Sarah
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$10,263
+60,372 vol $0.17 each |
2,160,425 | |
| Filed 2015-08-07 Tx date 2015-07-30 |
$SL
Supreme Pharmaceuticals Inc. |
Herburger, Peter
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$13,238
+77,876 vol $0.17 each |
2,154,929 | |
| Filed 2015-08-07 Tx date 2015-07-30 |
$SL
Supreme Pharmaceuticals Inc. |
Fowler, John Alexander
8 - Deemed Insider - 6 Months before becoming Insider
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$16,161
+95,067 vol $0.17 each |
2,087,620 | |
| Filed 2015-08-07 Tx date 2014-11-10 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Warrants exercisable at $0.50 per share prior to September 22, 2015
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2015-07-29 Tx date 2015-07-24 |
$SL
Supreme Pharmaceuticals Inc. |
Fowler, John Alexander
8 - Deemed Insider - 6 Months before becoming Insider
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,170
-6,500 vol $0.18 each |
1,992,553 | |
| Filed 2015-07-29 Tx date 2015-07-24 |
$SL
Supreme Pharmaceuticals Inc. |
Fowler, John Alexander
8 - Deemed Insider - 6 Months before becoming Insider
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,750
-10,000 vol $0.175 each |
1,999,053 | |
| Filed 2015-07-10 Tx date 2015-07-08 |
$SL
Supreme Pharmaceuticals Inc. |
Herburger, Peter
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,500
-7,500 vol $0.20 each |
2,077,053 | |
| Filed 2015-07-10 Tx date 2015-07-08 |
$SL
Supreme Pharmaceuticals Inc. |
Ruimy, James Aaron
8 - Deemed Insider - 6 Months before becoming Insider
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,600
-8,000 vol $0.20 each |
1,651,403 | |
| Filed 2015-07-10 Tx date 2015-07-08 |
$SL
Supreme Pharmaceuticals Inc. |
Herburger, Sarah
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-4,000
-20,000 vol $0.20 each |
2,100,053 | |
| Filed 2015-07-10 Tx date 2015-07-08 |
$SL
Supreme Pharmaceuticals Inc. |
Herburger, Peter
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-2,437.50
-12,500 vol $0.195 each |
2,084,553 | |
| Filed 2015-07-10 Tx date 2015-07-08 |
$SL
Supreme Pharmaceuticals Inc. |
Herburger, Peter
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,900
-10,000 vol $0.19 each |
2,097,053 | |
| Filed 2015-07-10 Tx date 2015-07-08 |
$SL
Supreme Pharmaceuticals Inc. |
Fowler, John Alexander
8 - Deemed Insider - 6 Months before becoming Insider
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-3,000
-15,000 vol $0.20 each |
2,009,053 | |
| Filed 2015-07-10 Tx date 2015-07-08 |
$SL
Supreme Pharmaceuticals Inc. |
Fowler, John Alexander
8 - Deemed Insider - 6 Months before becoming Insider
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-2,000
-10,000 vol $0.20 each |
||
| Filed 2015-07-10 Tx date 2015-07-08 |
$SL
Supreme Pharmaceuticals Inc. |
Fowler, John Alexander
8 - Deemed Insider - 6 Months before becoming Insider
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-2,000
-10,000 vol $0.20 each |
||
| Filed 2015-07-06 Tx date 2015-07-06 |
$SL
Supreme Pharmaceuticals Inc. |
Fowler, John Alexander
8 - Deemed Insider - 6 Months before becoming Insider
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,700
-10,000 vol $0.17 each |
2,024,053 | |
| Filed 2015-06-26 Tx date 2015-06-24 |
$SL
Supreme Pharmaceuticals Inc. |
Herburger, Peter
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,800
-10,000 vol $0.18 each |
2,107,053 | |
| Filed 2015-06-26 Tx date 2015-06-26 |
$SL
Supreme Pharmaceuticals Inc. |
Fowler, John Alexander
8 - Deemed Insider - 6 Months before becoming Insider
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-2,625
-15,000 vol $0.175 each |
2,034,053 | |
| Filed 2015-06-19 Tx date 2015-06-04 |
$SL
Supreme Pharmaceuticals Inc. |
Fowler, John Alexander
8 - Deemed Insider - 6 Months before becoming Insider
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,950
-10,000 vol $0.195 each |
2,064,053 | |
| Filed 2015-06-19 Tx date 2015-06-17 |
$SL
Supreme Pharmaceuticals Inc. |
Herburger, Peter
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-190.00
-1,000 vol $0.19 each |
2,117,053 | |
| Filed 2015-06-19 Tx date 2015-06-12 |
$SL
Supreme Pharmaceuticals Inc. |
Herburger, Peter
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-190.00
-1,000 vol $0.19 each |
2,118,053 | |
| Filed 2015-06-19 Tx date 2015-06-05 |
$SL
Supreme Pharmaceuticals Inc. |
Fowler, John Alexander
8 - Deemed Insider - 6 Months before becoming Insider
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-3,075
-15,000 vol $0.205 each |
2,049,053 | |
| Filed 2015-06-01 Tx date 2015-05-29 |
$SL
Supreme Pharmaceuticals Inc. |
Herburger, Peter
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-2,000
-10,000 vol $0.20 each |
2,129,053 | |
| Filed 2015-06-01 Tx date 2015-05-29 |
$SL
Supreme Pharmaceuticals Inc. |
Herburger, Sarah
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-2,100
-10,000 vol $0.21 each |
2,120,053 | |
| Filed 2015-06-01 Tx date 2015-05-29 |
$SL
Supreme Pharmaceuticals Inc. |
Herburger, Peter
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-2,100
-10,000 vol $0.21 each |
2,119,053 | |
| Filed 2015-05-12 Tx date 2015-05-07 |
$SL
Supreme Pharmaceuticals Inc. |
Herburger, Peter
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-2,200
-10,000 vol $0.22 each |
2,139,053 | |
| Filed 2015-05-11 Tx date 2015-05-07 |
$SL
Supreme Pharmaceuticals Inc. |
Fowler, John Alexander
8 - Deemed Insider - 6 Months before becoming Insider
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,912.50
-8,500 vol $0.225 each |
2,094,053 | |
| Filed 2015-05-11 Tx date 2015-05-08 |
$SL
Supreme Pharmaceuticals Inc. |
Ruimy, James Aaron
8 - Deemed Insider - 6 Months before becoming Insider
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,650
-7,500 vol $0.22 each |
1,659,403 | |
| Filed 2015-05-11 Tx date 2015-05-07 |
$SL
Supreme Pharmaceuticals Inc. |
Herburger, Sarah
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-2,200
-10,000 vol $0.22 each |
2,130,053 | |
| Filed 2015-05-11 Tx date 2015-05-11 |
$SL
Supreme Pharmaceuticals Inc. |
Fowler, John Alexander
8 - Deemed Insider - 6 Months before becoming Insider
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,350
-6,000 vol $0.225 each |
2,074,053 | |
| Filed 2015-05-11 Tx date 2015-05-08 |
$SL
Supreme Pharmaceuticals Inc. |
Fowler, John Alexander
8 - Deemed Insider - 6 Months before becoming Insider
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-3,150
-14,000 vol $0.225 each |
2,080,053 | |
| Filed 2015-05-11 Tx date 2015-05-06 |
$SL
Supreme Pharmaceuticals Inc. |
Fowler, John Alexander
8 - Deemed Insider - 6 Months before becoming Insider
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,462.50
-6,500 vol $0.225 each |
2,102,553 | |
| Filed 2015-04-28 Tx date 2015-04-23 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
+400,266 vol |
2,100,266 | |
| Filed 2015-04-28 Tx date 2015-04-23 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Convertible Debentures mature April 23, 2018
16 - Acquisition or disposition under a prospectus exemption
|
+$153,000 vol |
$153,000 | |
| Filed 2015-04-28 Tx date 2014-11-10 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Convertible Debentures mature April 23, 2018
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2015-04-28 Tx date 2015-04-23 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Warrants exercisable at $0.17 per share prior to April 23, 2020
16 - Acquisition or disposition under a prospectus exemption
|
+400,266 vol |
1,300,266 | |
| Filed 2015-04-28 Tx date 2015-04-23 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Warrants exercisable at $0.17 per share prior to April 23, 2020
16 - Acquisition or disposition under a prospectus exemption
|
+900,000 vol |
900,000 | |
| Filed 2015-04-28 Tx date 2014-11-10 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Warrants exercisable at $0.17 per share prior to April 23, 2020
00 - Opening Balance-Initial SEDI Report
|